ZyVersa Therapeutics, Inc.
ZVSA
$0.1221
-$0.0079-6.08%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.58% | -30.64% | -34.38% | -41.55% | -32.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.51% | -33.19% | -36.64% | -46.01% | -44.01% |
| Operating Income | 24.51% | 33.19% | 36.64% | 46.01% | 44.01% |
| Income Before Tax | 63.00% | 91.66% | 91.27% | 77.92% | 77.59% |
| Income Tax Expenses | 99.49% | 100.08% | 100.07% | 93.89% | 93.89% |
| Earnings from Continuing Operations | 62.02% | 90.94% | 90.42% | 76.20% | 75.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.02% | 90.94% | 90.42% | 76.20% | 75.86% |
| EBIT | 24.51% | 33.19% | 36.64% | 46.01% | 44.01% |
| EBITDA | 24.48% | 33.18% | 36.64% | 46.03% | 44.03% |
| EPS Basic | 95.68% | 99.60% | 99.43% | 96.11% | 95.05% |
| Normalized Basic EPS | 90.57% | 95.01% | 96.52% | 93.96% | 86.10% |
| EPS Diluted | 95.68% | 99.60% | 99.43% | 96.11% | 95.05% |
| Normalized Diluted EPS | 90.57% | 95.01% | 96.52% | 93.96% | 86.10% |
| Average Basic Shares Outstanding | 515.62% | 601.41% | 1,040.05% | -97.10% | -98.07% |
| Average Diluted Shares Outstanding | 515.62% | 601.41% | 1,040.05% | -97.10% | -98.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |